{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-050800","form_type":"8-K","ticker":"ABOS","cik":"0001576885","company_name":"Acumen Pharmaceuticals, Inc.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.803645+00:00","generated_at":"2026-05-16T22:22:58.877962+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Acumen appoints George Golumbeski as Chairman, replaces Sean Stalfort","bullets":["Dr. George Golumbeski appointed as director and Chairman of Board, effective Nov 6, 2025.","Golumbeski received initial option to buy 50,000 shares at closing price, vesting over 3 years.","Annual retainer: $40,000 for board service plus $30,000 as Chairman.","Board now has 8 members; Golumbeski brings 30+ years biopharma experience from Celgene, Novartis.","Company highlights Phase 2 sabirnetug trial and Enhanced Brain Delivery program as key 2026 catalysts."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-050800","json":"https://secwatch.observer/filing/0001628280-25-050800.json","markdown":"https://secwatch.observer/filing/0001628280-25-050800.md","text":"https://secwatch.observer/filing/0001628280-25-050800.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576885/000162828025050800/0001628280-25-050800-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576885/000162828025050800/abos-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:22:58.877962+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}